REVIEW article
Front. Immunol.
Sec. Cytokines and Soluble Mediators in Immunity
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1657285
This article is part of the Research TopicAdvancing Musculoskeletal Health: Bridging Basic and Clinical Research on Biomechanical Properties of Joints, Ligaments, Tendons, and Associated StructuresView all 10 articles
Mechanistic insights into IL-1β-mediated progression of tendinopathy
Provisionally accepted- 1Southwest Medical University, Luzhou, China
- 2Luzhou Medical College, Luzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Tendinopathy, a chronic degenerative musculoskeletal disorder characterized by pain, edema, and functional impairment, exhibits increased prevalence among elderly populations and athletes. Despite extensive research efforts targeting the attenuation of this degenerative process, clinical outcomes frequently remain suboptimal. Recent evidence underscores the critical need for more precisely targeted modulation of inflammatory pathways to improve therapeutic efficacy. Notably, the proinflammatory cytokine interleukin-1β (IL-1β) has been implicated as a prominent mediator in the pathogenesis of tendinopathy. This review synthesizes current understanding of IL-1β synthesis and its downstream signaling transduction pathways, with the primary objective of elucidating the mechanisms by which IL-1β contributes to tendinopathy progression. Through this approach, we seek to reveal novel therapeutic targets and inform improved management strategies. Although IL-1β represents a promising therapeutic candidate for tendinopathy, as evidenced by numerous investigations, current understanding of its pathogenic role is limited by several factors, including the heterogeneity of experimental models, a lack of translational studies, and insufficient evidence linking IL-1β signaling to specific clinical manifestations. Consequently, further research is essential to delineate the precise mechanisms of IL-1β involvement in tendinopathy.
Keywords: IL-1β, Tendinopathy, Pathogenesis, therapeutic targets, proinflammatory cytokines
Received: 01 Jul 2025; Accepted: 15 Oct 2025.
Copyright: © 2025 Zhang, Wang, Tang, Yang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guiquan Chen, lhynn1113@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.